The network, established with funding from the National Institutes of Health, has the the ultimate goal of developing more effective brain-aging treatments and interventions targeted to the individual.
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died
Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide
If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19Continue reading
On Sep 30, 2021, the Arizona Business Innovation Awards, presented by Az Business magazine honored the 30 most innovative companies in Arizona. In addition to honoring the 30 most innovative companies in Arizona for 2021, the judges also selected five spotlight award winners for exceptional achievement.Continue reading
The University of Arizona BIO5 Institute KEYS Research Internship recruitment for KEYS 2022 has officially begun!
Maetzold’s presentation will take place during the AZAdvances Life Science Innovation Showcase on October 6Continue reading
InerOme, University of California San Diego, and Fry Laboratories published an article in the Journal of Precision Medicine, detailing a cloud based digital health Surveillance of Wastewater and Prevention Platform for COVID-19.
The ISO 13485:2016 registration positions Humabiologics among the first global providers of GMP (Good Manufacturing Practices) grade human-derived biomaterials to support and expedite the future development of human regenerative therapies and tissue models for drug discovery through clinically relevant high-quality products. Continue reading